Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
November 5, 2019 7:30 AM ESTNEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2019.
I am pleased with the significant progress we have made in the third quarter across our commercial, regulatory, and clinical initiatives, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. We... More
